|The molecular portraits of breast tumors are conserved across microarray platforms|
Z Hu, C Fan, DS Oh, JS Marron, X He, BF Qaqish, C Livasy, LA Carey, ...
BMC genomics 7 (1), 1-12, 2006
|Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma|
CA Livasy, G Karaca, R Nanda, MS Tretiakova, OI Olopade, DT Moore, ...
Modern pathology 19 (2), 264-271, 2006
|Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study|
R Nanda, LQM Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
Journal of Clinical Oncology 34 (21), 2460, 2016
|Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer|
D Huo, F Ikpatt, A Khramtsov, JM Dangou, R Nanda, J Dignam, B Zhang, ...
Journal of Clinical Oncology 27 (27), 4515, 2009
|Adaptive randomization of veliparib–carboplatin treatment in breast cancer|
HS Rugo, OI Olopade, A DeMichele, C Yau, LJ van’t Veer, MB Buxton, ...
New England Journal of Medicine 375 (1), 23-34, 2016
|A genome-wide screen for promoter methylation in lung cancer identifies novel methylation markers for multiple malignancies|
DS Shames, L Girard, B Gao, M Sato, CM Lewis, N Shivapurkar, A Jiang, ...
PLoS Med 3 (12), e486, 2006
|Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study|
LA Emens, C Cruz, JP Eder, F Braiteh, C Chung, SM Tolaney, I Kuter, ...
JAMA oncology 5 (1), 74-82, 2019
|Adaptive randomization of neratinib in early breast cancer|
JW Park, MC Liu, D Yee, C Yau, LJ van’t Veer, WF Symmans, M Paoloni, ...
New England Journal of Medicine 375 (1), 11-22, 2016
|Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study|
S Adams, P Schmid, HS Rugo, EP Winer, D Loirat, A Awada, DW Cescon, ...
Annals of Oncology 30 (3), 397-404, 2019
|Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry|
R Nanda, LP Schumm, S Cummings, JD Fackenthal, L Sveen, ...
Jama 294 (15), 1925-1933, 2005
|Advances in breast cancer: pathways to personalized medicine|
OI Olopade, TA Grushko, R Nanda, D Huo
Clinical Cancer Research 14 (24), 7988-7999, 2008
|Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2 …|
MF Rimawi, IA Mayer, A Forero, R Nanda, MP Goetz, AA Rodriguez, ...
Journal of clinical oncology 31 (14), 1726, 2013
|BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy|
M Wei, TA Grushko, J Dignam, F Hagos, R Nanda, L Sveen, J Xu, ...
Cancer research 65 (23), 10692-10699, 2005
|Enzalutamide for the treatment of androgen receptor–expressing triple-negative breast cancer|
TA Traina, K Miller, DA Yardley, J Eakle, LS Schwartzberg, ...
Journal of clinical oncology 36 (9), 884, 2018
|Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2.|
R Nanda, MC Liu, C Yau, S Asare, N Hylton, LV Veer, J Perlmutter, ...
Journal of Clinical Oncology 35 (15_suppl), 506-506, 2017
|Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study|
S Adams, S Loi, D Toppmeyer, DW Cescon, M De Laurentiis, R Nanda, ...
Annals of Oncology 30 (3), 405-411, 2019
|The role of tumor-associated macrophages in breast cancer progression|
E Obeid, R Nanda, YX Fu, OI Olopade
International journal of oncology 43 (1), 5-12, 2013
|Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).|
TA Traina, K Miller, DA Yardley, J O'Shaughnessy, J Cortes, A Awada, ...
Journal of clinical oncology 33 (15_suppl), 1003-1003, 2015
|Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer: Translational Breast Cancer …|
JF De Los Santos, A Cantor, KD Amos, A Forero, M Golshan, JK Horton, ...
Cancer 119 (10), 1776-1783, 2013
|A phase Ib study of pembrolizumab (MK-3475) in patients with advanced triple-negative breast cancer|
R Nanda, LQ Chow, EC Dees, R Berger, S Gupta, R Geva, L Pusztai, ...
San Antonio Breast Cancer Symposium, 9-13, 2014